Martin R. Prince1,2, Honglei Zhang1, Zhitong Zou1, Ronale B. Staron2, Paula W. Brill1
1Radiology, Weill Cornell Medical College, New York, NY, United States; 2Radiology, Columbia College of Physicians & Surgeons, New York, NY, United States
GBCA adverse events reported in 94 patients over 10 years were analyzed to determine their incidence. Immediate AE rates were 0.2, 0.5, 1.2 and 3.3 per 1,000 injections for gadodiamide, gadopentetate dimeglumine, gadobenate dimeglumine and gadoteridol. Gadobenate dimeglumine had more severe reactions (3 arrests, one of whom died). Abdominal MRI had the highest rates of AE, 0.013% compared to brain (0.0045%) or spine (0.0034%). From 2004 to 2009 FDA received reports on 40 GBCA US deaths unrelated to NSF with an incidence of < 1 death per million (40 deaths/51 million GBCA administrations) indicating GBCA are extraordinarily safe.